Roche's Divarasib Shows Statistically Significant Progression-Free And Overall Survival Gains Versus Sotorasib Or Adagrasib In NSCLC Study

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBF

0.00

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHVF

0.00
  • Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer 
  • Divarasib showed clinically meaningful improvements in progression-free survival compared to approved  KRAS G12C inhibitors; no new safety signals were observed
  • Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population
  • Data will be submitted to health authorities and presented at an upcoming medical meeting
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.